Literature DB >> 32636935

Factors affecting operative time during ureteroscopy and stone treatment and its effect on outcomes: retrospective results over 6.5 years.

Lily Whitehurst1, Amelia Pietropaolo1, Robert Geraghty1, Rena Kyriakides1, Bhaskar K Somani2.   

Abstract

BACKGROUND: We aimed to evaluate operative time with the outcomes of ureteroscopy (URS) and investigate the relationship between these factors, and assess if longer operative times were associated with a higher risk of complications.
METHODS: We retrospectively audited consecutive cases of URS done between March 2012 and June 2018. Data were collected for operative times, patient demographics, stone parameters, stent insertions, use of ureteric access sheath, length of stay, stone-free rate (SFR) and complications. Statistical analysis was performed using IBM SPSS version 24.
RESULTS: Over 6.5 years, 736 patients with a male:female ratio of 1.8:1 and a mean age of 54.7 years (range: 2-91 years), underwent 860 URS and stone treatment procedures. The mean operative time was 43.5 min (range: 8-160 min), with a stone size of 12.3 mm (range: 3-100 mm) and access sheath was used in 35.8%. The initial and final SFR was 86% and 92.5%, respectively, and 85.6% (n = 736) patients were discharged the same day of procedure. Treatment of multiple renal stones, ureteric and renal stones, large stones, use of access sheath and post-operative stent were all associated with longer operative times (p <0.001). Patients who were stone free and those having day-case procedures had shorter operative times (p <0.001). There were 27 (3.2%) Clavien I/II complications and 8 (0.9%) Clavien ⩾III complications. Clavien score ⩾III (p = 0.028) and infectious complications (p <0.001) had significantly longer operative times.
CONCLUSION: Patients with shorter operative times have a higher chance of being discharged home the same day without a post-operative stent. Higher operative times are associated with high-grade, especially infection-related, complications.
© The Author(s), 2020.

Entities:  

Keywords:  complications; operative time; stone; ureteroscopy; urolithiasis

Year:  2020        PMID: 32636935      PMCID: PMC7313327          DOI: 10.1177/1756287220934403

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


Introduction

Ureteroscopy (URS), with semi-rigid and flexible scopes, has revolutionised the management of ureteric and renal stones. With the development of high-powered lasers, new techniques have been established for stone fragmentation such as dusting and pop-dusting, allowing larger stones to be treated more efficiently.[1] The use of ureteric access sheaths (UAS) also improves stone-free rates (SFRs), as it facilitates clearer views in the kidney with low intrarenal pressure and allows repeated re-entry to the kidney to clear fragments in a time-effective manner, in addition to decreasing the infectious complications.[2] Given the rising prevalence of stone disease, the number of URS procedures performed has increased by 252% over the past 2 decades.[3] This has consequently led to an increased workload for endourologists. It has been shown that in centres with a higher workload, URS has shorter operative times, improved SFRs and lower complication rates.[4] There seems to be a lack of consensus in urology that supports the correlation of shorter operative times of URS with improved patient outcomes. A recent general surgical study from the USA found that patients undergoing longer elective laparoscopic procedures had significantly higher complication rates, even after adjusting for patient factors.[5] Similarly, a recent orthopaedic study[6] analysed the complication rates for total joint replacement, and demonstrated that operative times greater than 120 min were associated with increased wound complications; whereas shorter operative times (less than 60 min) had significantly lower wound complication rates. Percutaneous nephrolithotomy (PCNL) which required longer operative times have already been directly correlated to increased adverse outcomes,[7] which increased linearly with every additional 60-min increase in operative duration. Similarly, there are studies which show a higher risk of complications with longer procedural time with URS.[8,9] We wanted to establish whether similar findings would also apply to ureteroscopic stone surgery specifically, and therefore we set out to analyse consecutive cases of URS at a high-volume tertiary centre, with an experienced endourologist. Our aim was to evaluate operative time with the outcomes of URS, including its complications and SFR, and investigate the relationship between these factors.

Methods

Data collection

We interrogated the database of consecutive URS procedures at our institution (March 2012–June 2018) via retrospective analysis. Informed consent for participation in endourology research was obtained from all patients during their URS procedure. The audit was registered with our ‘Clinical Effectiveness and Audit’ office. Extracted data included operative times, patient demographics, stone parameters (size, number, location and multiplicity), pre- and post-operative stent insertions, use of UAS, length of stay, SFR and its complications. All URS procedures done for the treatment of stones in patients of all age groups were included, and URS for diagnostic or upper-tract tumour treatments were excluded.

Pre-operative assessment

Stone diagnosis was confirmed using a non-contrast computed tomography (CT) scan kidney–ureter–bladder (CT KUB) for patients >16 years and ultrasound scan (USS) for patients ⩽16 years. Patients underwent a protocol-based pre-assessment with routine blood tests, including renal function, urinalysis and urine culture. To optimise patients prior to the procedure, a dedicated uro-anaesthetist reviewed all identified high-risk patients. Patients with a positive urine culture were given appropriate sensitivity-based antibiotics, with a repeat urine culture arranged. If necessary, up-to-date renal tract imaging was also organised in consultation with the surgeon.

Ureteroscopic procedure

A standardised protocol-based procedure was carried out for all patients, and antibiotic prophylaxis was given during the induction of general anaesthesia.[10] After the placement of a safety guidewire, a semi-rigid URS was carried out (4.5 or 6F ureteroscope) to the ureteric stone or as far proximally as safely achievable. For renal stones, if appropriate, a UAS (9.5 F/11.5 F or 12 F/14 F Cook Flexor sheath) was inserted over a second guidewire. A flexible ureteroscope (Storz FlexX2) was used for renal stones. Laser stone fragmentation was performed with a 20 W or 100 W Holmium YAG laser [Versa Pulse Holmium Powersuite 100 W or 20 W Lumenis (UK) Ltd., Elstree, UK] using a 272 μm laser fibre (Lumenis, Inc.) and/or basket extraction. The technique used was stone fragmentation, dusting or pop-dusting, and larger fragments were removed with a Cook NGage nitinol stone extractor (1.7 F or 2.2 F, Cook Medical, USA). A 6 F ureteric stent was placed at the end of the procedure and removed subsequently. Unless clinically indicated, a routine post-operative urethral catheter was not placed, and patients were discharged home the same day.

Outcomes

Operative time duration (in minutes) was calculated from the insertion of cystoscope (scope insertion) to the removal of all devices after the completion of the procedure and bladder emptying (scope removal). Stone size was calculated by measuring the maximum stone diameter on CT scan or for multiple stones, a sum of maximal dimensions of each stone. Day-case discharges were defined as patients discharged on the same day as having undergone the procedure. We classified patient complications using the Clavien–Dindo scoring system.[11] All patients with radio-opaque stones underwent plain X-ray (XR) KUB and those with radiolucent stone underwent a USS to establish an SFR. In selected cases, if there was a concern regarding residual fragments on a USS where the findings were contradictory to the endoscopic findings; or if the scan was equivocal, a CT KUB was performed. The SFR was defined as complete clearance of the stone endoscopically and clinically insignificant fragments (⩽2 mm) on post-operative imaging done 2–4 months in our dedicated kidney-stone clinic. Patients who were endoscopically and/or radiologically stone free at the end of the URS procedure (as recorded on electronic theatre notes) and were symptom free at stent removal with no re-admissions but did not attend follow-up were presumed to be stone free.

Statistical analysis

Data were recorded on a Microsoft Excel spreadsheet and statistical analysis was performed using IBM SPSS version 24. Analysis was undertaken with simple and multiple linear regression. Statistics are presented with 95% confidence interval, standardised beta coefficient, and p value. Adjustments were made for all variables, and a p value <0.05 was considered statistically significant.

Results

Over the study period of 6.5 years, 736 consecutive patients with a male:female ratio of 1.8:1 and a mean age of 54.7 years (range: 2–91 years), underwent 860 URS and stone treatment. Of these, 632, 84 and 20 patients underwent one, two and three procedures, respectively (1.16 procedure/patient). The mean operative time was 43.5 min (range: 8–160 min), and UAS were used in 35.8% (n = 308) of cases. The mean single and cumulative stone size were 9.1 mm (3–40 mm) and 12.3 mm (range: 3–100 mm), wherein 30.8% (n = 265) of patients had multiple stones, 11.7% (n = 101) had simultaneous renal and ureteric stone treatment. Mean operative times with stone location and cumulative stone length is displayed in Figure 1. The mean operative times were higher for larger stones and for renal stones compared with ureteric stones. The initial and final SFR was 86% and 92.5%, respectively, and 85.6% (n = 736) patients were discharged the same day of procedure. Each of the parameters correlated with their differing operative times are shown in Table 1.
Figure 1.

Operative times correlated with stone location and cumulative stone length.

CI, confidence interval; PUJ, pelvi-ureteric junction; VUJ, vesico-ureteric junction.

Table 1.

Correlation of operative times with outcomes.

860 procedures(736 patients)Yes (n, %)Operative time (min)No (n, %)Operative time (min)Standardised beta coefficientp value
Pre-op stent281 (32.7%)44.86 ± 24.81579 (67.3%)43.28 ± 24.810.040.28
Simultaneous renal and ureteric stones101 (11.7%)50.80 ± 31.81759 (88.3%)43.50 ± 24.200.15<0.001
Stone multiplicity265 (30.8%)51.64 ± 27.94595 (69.2%)40.26 ± 22.880.080.06
Access sheath use (unavailable, n = 38)308 (35.8%)55.09 ± 26.33514 (59.8%)37.2 ± 22.330.239<0.001
Stone free681 (92.5%)42.09 ± 24.3055 (7.5%)64.77 ± 28.60−0.18<0.001
Post-op stent (unavailable, n = 17)688 (81.6%)45.6 ± 25.1155 (18.4%)34.8 ± 24.90.18<0.001
Day case736 (85.6%)42.04 ± 24.12124 (14.4%)53.81 ± 29.950.15<0.001
Complications37 (4.3%)55.86 ± 33.47823 (95.7%)43.48 ± 24.910.050.11
Clavien I–II0.0580.08
Clavien ⩾III0.0690.03
Infectious complications0.0650.05
Non-infectious complications0.0060.85
Operative times correlated with stone location and cumulative stone length. CI, confidence interval; PUJ, pelvi-ureteric junction; VUJ, vesico-ureteric junction. Correlation of operative times with outcomes.

Multivariate linear regression

The results of the linear regression, including the standardised beta coefficient and p values for all variables are displayed in Table 1. Access-sheath use was associated with significantly increased operative time in minutes (37.2 ± 22.33 versus 55.09 ± 26.33; standardised beta 0.239, p <0.001). Patients with simultaneous renal and ureteric stones were also shown to have significantly longer procedures (50.80 ± 31.81 versus 43.50 ± 24.20; standardised beta 0.15, p <0.001). Larger stones were found in the proximal ureter, pelvi-ureteric junction or kidney, and these required consequently longer operative times, which is also supported by the findings in Table 2. Patients who were stented at the end of the procedure had longer operative times (45.6 ± 25.1 versus 34.8 ± 24.9; standardised beta 0.18, p value <0.001). Stone-free procedures were the only parameter associated with significantly decreased operative times (42.09 ± 24.30 versus 64.77 ± 28.60; standardised beta −0.18, p <0.001). Complication rates were not associated with longer operative times in general, but when split into the Clavien–Dindo classifications, we found that patients with Clavien score ⩾III did have significantly longer operative times (standardised beta 0.069, p = 0.028). Similarly, patients with infectious complications were found to have significantly longer operative times (standardised beta 0.065, p <0.001). Patients who required hospital admission after their procedure had longer operative times than those patients done as a day-case procedure (42.04 ± 24.12 versus 53.81 ± 29.95; standardised beta 0.15, p <0.001). Age, family history and sex were not significantly associated with operative times.
Table 2.

Correlation of stone size and outcomes with operative times.

LocationMean operative time, min ± SD (if no SD, n = 1)
<5 mm6–10 mm11–15 mm16–20 mm>20 mm
VUJ22 ± 1327 ± 1635 ± 1827
Distal ureter24 ± 1335 ± 2043 ± 2240 ± 1386
Mid ureter30 ± 1535 ± 1850 ± 262757
Proximal ureter37 ± 1934 ± 1447 ± 4039 ± 1385
PUJ25 ± 1739 ± 1752 ± 2170 ± 2297 ± 8
Renal pelvis30 ± 1337 ± 2161 ± 3061 ± 1761 ± 16
Lower pole26 ± 1239 ± 1743 ± 1262 ± 3069 ± 23
Mid pole32 ± 1042 ± 2549 ± 2372 ± 2791 ± 39
Upper pole27 ± 1643 ± 2846 ± 1574 ± 2265 ± 7

PUJ, pelvi-ureteric junction; SD, standard deviation; VUJ, vesico-ureteric junction.

Correlation of stone size and outcomes with operative times. PUJ, pelvi-ureteric junction; SD, standard deviation; VUJ, vesico-ureteric junction.

Complications

The full list of complications can be seen in Table 3. There were 35 (4.1%) complications (26 were Clavien I/II, 1 Clavien III and 7 Clavien IV complications) with no deaths in our series. The mean operative time and range are also shown in this table. These complications were stent symptoms (n = 8), urinary tract infection (n = 7), urosepsis (n = 14) and others (n = 6; Table 3). Clavien ⩾III complications and infection-related complications had significantly longer operative time duration.
Table 3.

Correlation of complications with outcomes.

Complications(n = 35)Number of patientsClavien–Dindo scoreMean operative duration (min)
Stent symptoms8I45.0 (16–76)
Clot colic (unstented)116.0
Urinary tract infection7II74.0 (38–112)
Urosepsis863.0 (19–132)
Aspiration pneumonia155.0
Haematuria requiring irrigation236.5 (35–38)
Urosepsis and stent migration1IIIa29.0
Urosepsis requiring ITU admission5IVa77.8 (19–132)
Respiratory complication (requiring ITU admission)253.5 (49–58)

ITU, intensive therapy unit.

Correlation of complications with outcomes. ITU, intensive therapy unit.

Discussion

Meaning of the study

Our results of a consecutive 860 procedures over 6.5 years show excellent SFR with low risk of complication rates. While there were no intra-operative complications, there were only 27 (3.2%) Clavien I/II complications and 8 (0.9%) Clavien ⩾III complications. Figure 1 shows that the operative times correlated with stone location and cumulative stone length. Treatment of multiple renal stones, ureteric and renal stones, large stones, use of access sheath were all associated with longer operative times. While there was no difference in the operative time with the use of pre-operative stents, patients without post-operative stents and those done as a day-case procedure had significantly lower operative times. Operative time was also associated with higher Clavien-grade complications and those with infectious complications.

Implications of URS operative time from previously published literature

It is known that larger stones need longer procedural time for stone clearance, although it is difficult to ascertain the point at which they become too long, potentially risking complications[12-22] (Table 4). A retrospective study[14] from Japan analysed a database of over 12,000 URS patients, demonstrating that a cut-off time over 90 min significantly increased rates of adverse events, mortality and ITU admissions. Higher stone burden and the location of the stone have an impact on the operation time, which was also demonstrated by Deters et al.[15] They retrospectively analysed 213 patients (54% ureteric, 46% renal) and found that renal stones required significantly longer operative times (112 versus 70, p <0.001). Our data also support this, with longer times also seen in patients with simultaneous ureteric and renal stones.
Table 4.

Literature review of operative times with outcomes.

AuthorsNumber of patientsStudy typeOperative time(min)Stone sizeMultiplicityStone location (% ureteric, renal, mixed)Access sheathComplicationsRecommendations for operative times
Pietropaolo et al.[1]860ProspectiveMean 43.512.3 mm30.8%35.8%4.1% (35)See Table 3UAS are safe, and beneficial for effective stone clearance, though associated with longer operative timesIncreased operative times are significantly associated with higher Clavien grade and infectious complications
Knipper et al.[12]2010RetrospectiveMedian 357 mmMedian of single stone14.3% (298)Bleeding, ureteral perforation, extravasation, mucosal injury, ureteric avulsion, UTI, hydronephrosis and sepsisOperative time significantly higher in patients who had a complicationSignificant difference with larger stone size, and stone-free rate in patient with complications
Ogzor et al.[13]494ProspectiveMean 65.3 (infectious group)[*] versus 47.8 (non-infectious)182.4 mm[3] and 161.3 mm[3]30.4%19.6%, 50%, 30.4%3.2% (16)Haemorrhage, thermal injury, perforationOperative times >60 min increased complication rates by 2.36-fold(exclusions: patients with bleeding diathesis, neurogenic bladder, ureteric stone, immunosuppressed, pregnancy, digital URS, presence of nephrostomy or positive urine culture)
Sugihara et al.[14]12372Retrospective2.39% (296)
Deters et al.[15]213RetrospectiveMean 115 (renal) versus 98 (ureteric)11.3 mm (renal) and 7.7 mm (ureteric)Single stones only54%, 46%, 0%3.3% (7)Pain, retained stent, stent migration, ureteral strictureRenal stones required significantly longer operative timesPre-operative stenting did not decrease operative times
Fan et al.[16]227RetrospectiveMean 99.42 (infectious group)[*] versus 73.37 (non-infectious)2.06 cm versus 1.66 cmNot stated8.37% (19)Fever and rigors, SIRS and sepsisPatients with longer operative times than 90 min had higher infective complication rates
Galal et al.[17]135RetrospectiveMean 40.9 (rigid URS) versus 48.4 (flexible URS)13.5mm versus 12.9 mmNot stated100% ureteric24.4% (33)Haematuria, renal colic, fever, UTI and ureteric perforationOperative times were statically proven to be shorter with rigid URS
Ito et al.[23]233RetrospectiveMean 74.0425 mm[3] (op time <90 mins) versus 934.6 mm[3] (>90 mins)Not stated95.7%6.4% (15)High-grade fever, ureteric strictures requiring balloon dilatationLonger operative times with stone volume, maximum Hounsfield units, absence of pre-stenting and the number of procedures carried out by the surgeon (prolonged if less experience)
Chu et al.[19]104RetrospectiveMean in <1 cm:Presented 86 ± 9.2Non-stented >1 cm 123.6 ± 59.81 cm(range 0.3–4 cm)Not stated78%, 22%, 0%1% (1)PyelonephritisPre-stenting allows shorter operating times as the ureter is passively dilated, allowing for larger access sheaths to be used
Sorokin et al.[20]118RetrospectiveMean 50.1 (±25.9 SD)10.2 cm (±4.4 SD)Not stated100% renal41%Not statedStone volume had the strongest impact on operative time, can be used to predict time by adding 2 min per 100 mm[3]
Wolff et al.[21]307ProspectiveMedian 35 (23–55)6 mm (4–8)22.1%61.6%, 38.4%, 0%)10.8% (33)No significant difference between experienced specialists and trainees performing URS with patient outcomes
Kuroda et al.[22]472[**]Retrospective80.3 ± 33.7,109.2 ± 34.4,110.5 ± 23.0651.6 ± 690.5,1286.8 ± 1122.0,3725.9 ± 4354.52.0 ± 1.8,2.7 ± 1.9,3.3 ± 2.5Ȓ100%4.9% (23)Post-operative fever, ureteral stricture

Patients were split into two groups; those with infectious complications and those without.

Patients were divided into stone-free groups: those with <4 mm fragments; and those with >4 mm fragments.

SD, standard deviation; SIRS, systemic inflammatory response syndrome; UAS, ureteric access sheaths; URS, ureteroscopy; UTI, urinary tract infection.

Literature review of operative times with outcomes. Patients were split into two groups; those with infectious complications and those without. Patients were divided into stone-free groups: those with <4 mm fragments; and those with >4 mm fragments. SD, standard deviation; SIRS, systemic inflammatory response syndrome; UAS, ureteric access sheaths; URS, ureteroscopy; UTI, urinary tract infection. UAS are beneficial in URS, as they allow repeated access to the kidney, lower intrarenal pressure and allow clear views.[24] UAS were used in 35.8% of our cases and associated with significantly increased operative times (55.1 min versus 37.2 min). This is in keeping with the findings of Sorokin et al. who found that UAS use was associated with an average increase of 13.5 min per procedure.[20] In the CROES global study, UAS had no impact on the SFR but was associated with fewer infectious complications.[2] This supports our conclusion that provided UAS use is safe, the benefits for effective stone clearance in high stone burden outweigh the risks of a slight increase in operative duration. Intuitively, patients with pre-operative stents should have lower operative times given that the ureter is already passively dilated and would accommodate a ureteroscope more readily.[25] Similarly, patients with narrow ureters are more likely to have successful URS after a period of time with a stent in place.[26] In a retrospective study, it was found that pre-operative stenting can decrease operative times for stones that are ⩾1 cm;[19] our analysis however showed no significant impact of pre-operative stenting on operative times. Our data did show that patients who were stented post-operatively had significantly longer operative times (45.6 versus 34.8 mins), which attributed to surgical decision making, as patients with longer procedures had larger and more proximally located stones. A complication rate of 4.1% was found for our data, which compares favourably with the European Association of Urology, which quote overall complication rates for URS lithotripsy of 9–25%.[25,26] Several severe complications can occur following URS, including sepsis, bleeding, perforation, ureteric strictures and avulsion.[22] We found that increased operative duration was significantly associated with Clavien–Dindo ⩾III and infectious complications. There are several articles which have analysed specific outcomes of infectious complications following URS. Fan et al.[16] reported on 227 patients and found that the key risk factors for infectious complications were pre-operative pyuria (p = 0.017) and prolonged operative times (p = 0.026). They found that patients with an infectious complication had an operative time of 99.42 min (compared with their average of 75.2 min), which again supports that longer procedures are associated with increased adverse events. They recommended that antibiotics were given prior to URS in patients with proven pyuria. Ogzor et al.[13] also reported on infectious complications in a cohort of 494 patients and noted that the rates were higher in patients with abnormal renal anatomy, older age and longer operative duration (65 min versus 48 min). They found that specifically infectious complications increased by 2.4-fold in procedures longer than an hour.

Strengths, limitations and areas for future research

The strength of this study is that it is a large data set over the last 6.5 years. This is unselected and includes paediatric patients, emergency admissions, complex patients and regional referrals, with no exclusions. However, we did not have complete details of the pelvi-calyceal anatomy and therefore could not specifically look at the effect of this on operative outcomes of lower pole stones. Similarly, we did not routinely measure the Hounsfield unit (HU) of stones and there was a lack of long-term follow-up data for this cohort. HU is known to be a good indicator of stone composition, and a few authors have previously attempted to find some correlation between operative times and hardness of the stone.[23] Ito et al. in their retrospective analysis of 233 patients conclude that larger stone volume, low surgeon experience, high HU and lack of pre-operative stent were all associated with longer operative duration.[23] Conversely, Sorokin et al.[20] showed no predictive value of HU or stone composition, although stone volume was useful in determining the longer operative time. So, although HU was missing from our dataset, it is most likely of little clinical bearing. Complete information on patient comorbidities, stone composition and access sheath were also missing. The proportion of patients who had XR, USS or CT was not recorded, and the SFR was defined as fragments ⩽2mm, as opposed to totally stone free. Although current clinical guidelines have no operative time limit, it is clear that longer operative duration is associated with higher risk of complications, especially those related to urinary infections and urosepsis. This duration is not defined, but studies suggest that perhaps the upper limit should be 60–90 min beyond which a staged URS procedure or a different treatment modality should be approached.[13,16,18] Clearly, this would need to take into consideration pre-operative optimisation, urine culture, antibiotic prophylaxis for the procedure, intrarenal pressure and surgical expertise, all of which have been shown to affect complication rates. Perhaps there is a need for urology guidelines to address this issue to help clinicians on the ‘safe maximum operative time duration’ and a principle similar to the ‘as low as reasonably achievable’ in terms of keeping this procedural time to a minimum required for the job. Future studies would also need to look at the new thulium fibre laser which is meant to be two to fourfold faster than the current holmium laser.[27] Therefore, adoption of this new technology could potentially lower procedural times, possibly further decreasing complication rates.

Conclusion

Our study shows that operative times are longer while treating large, multiple stones, especially with the use of UAS. Patients with shorter operative times have a higher chance of being discharged home the same day without a post-operative stent. Longer operative times are associated with high-grade, especially infection-related, complications. These factors must be kept in mind for surgical planning while making decisions, and patient counselling, especially where multiple treatment options might apply.
  24 in total

Review 1.  Worldwide Trends of Urinary Stone Disease Treatment Over the Last Two Decades: A Systematic Review.

Authors:  Robert M Geraghty; Patrick Jones; Bhaskar K Somani
Journal:  J Endourol       Date:  2017-06       Impact factor: 2.942

2.  Fever and systemic inflammatory response syndrome after retrograde intrarenal surgery: Risk factors and predictive model.

Authors:  Tian Li; Xiang-Zhou Sun; De-Hui Lai; Xun Li; Yong-Zhong He
Journal:  Kaohsiung J Med Sci       Date:  2018-02-07       Impact factor: 2.744

Review 3.  Correlation of Operative Time with Outcomes of Ureteroscopy and Stone Treatment: a Systematic Review of Literature.

Authors:  Jenni Lane; Lily Whitehurst; B M Zeeshan Hameed; Theodoros Tokas; Bhaskar K Somani
Journal:  Curr Urol Rep       Date:  2020-03-24       Impact factor: 3.092

4.  Risk factors of infectious complications following flexible ureteroscope with a holmium laser: a retrospective study.

Authors:  Song Fan; Binbin Gong; Zongyao Hao; Li Zhang; Jun Zhou; Yifei Zhang; Chaozhao Liang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Does speed matter? The impact of operative time on outcome in laparoscopic surgery.

Authors:  Timothy D Jackson; Jeffrey J Wannares; R Todd Lancaster; David W Rattner; Matthew M Hutter
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

6.  Predictive value of attenuation coefficients measured as Hounsfield units on noncontrast computed tomography during flexible ureteroscopy with holmium laser lithotripsy: a single-center experience.

Authors:  Hiroki Ito; Takashi Kawahara; Hideyuki Terao; Takehiko Ogawa; Masahiro Yao; Yoshinobu Kubota; Junichi Matsuzaki
Journal:  J Endourol       Date:  2012-06-12       Impact factor: 2.942

7.  A nomogram predicting severe adverse events after ureteroscopic lithotripsy: 12  372 patients in a Japanese national series.

Authors:  Toru Sugihara; Hideo Yasunaga; Hiromasa Horiguchi; Hiroaki Nishimatsu; Haruki Kume; Kazuhiko Ohe; Shinya Matsuda; Kiyohide Fushimi; Yukio Homma
Journal:  BJU Int       Date:  2012-12-18       Impact factor: 5.588

8.  Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study.

Authors:  Olivier Traxer; Gunnar Wendt-Nordahl; Hiren Sodha; Jens Rassweiler; Shimon Meretyk; Ahmet Tefekli; Fernando Coz; Jean J de la Rosette
Journal:  World J Urol       Date:  2015-05-14       Impact factor: 4.226

9.  A new prediction model for operative time of flexible ureteroscopy with lithotripsy for the treatment of renal stones.

Authors:  Shinnosuke Kuroda; Hiroki Ito; Kentaro Sakamaki; Tadashi Tabei; Takashi Kawahara; Atsushi Fujikawa; Kazuhide Makiyama; Masahiro Yao; Hiroji Uemura; Junichi Matsuzaki
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  1 in total

1.  Role of low- versus high-power laser in the treatment of lower pole stones: prospective non-randomized outcomes from a university teaching hospital.

Authors:  Amelia Pietropaolo; Mriganka Mani; Thomas Hughes; Bhaskar K Somani
Journal:  Ther Adv Urol       Date:  2022-05-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.